The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.
The FDA has designated Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.
The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback